Stephen Squinto, Gennao Bio CEO (Gennao)

Alex­ion co-founder Stephen Squin­to is back in the game as CEO, this time for a small gene ther­a­py play­er

With his name al­ready be­hind a rare dis­ease suc­cess sto­ry in Alex­ion, Stephen Squin­to was look­ing for a great sto­ry to dri­ve him to jump back in­to the biotech game. He found that in a fledg­ing non-vi­ral gene ther­a­py com­pa­ny, and now he’s got a few back­ers on board as well.

On Tues­day, Gen­nao Bio launched with a $40 mil­lion Se­ries A co-led by Or­biMed and Lo­gos Cap­i­tal with par­tic­i­pa­tion by Sur­vey­or Cap­i­tal. The biotech, which is look­ing to use its cell-pen­e­trat­ing an­ti­body plat­form to de­liv­er nu­cle­ic acid “pay­loads” dur­ing in­to the nu­cle­us, had to rush for its ini­tial se­ries — and had a name change along the way.

“This sort of hap­pened so quick­ly, and we al­so went through a name change re­cent­ly — we were called some­thing else up un­til a month ago,” CEO Stephen Squin­to told End­points News. “We’ve en­gaged with a firm to de­vel­op mes­sag­ing and a new lo­go; we should have one some­time in the next three or four weeks.”

The com­pa­ny was co-found­ed in 2020 by Squin­to, Yale pro­fes­sors Pe­te Glaz­er, Elias Qui­jano and Bruce Turn­er af­ter it re­ceived fund­ing from the Blavat­nik Fund for In­no­va­tion at Yale, named for Len Blava­tinik, a bil­lion­aire busi­ness­man who is a chair­man for Ac­cess In­dus­tries. With the $40 mil­lion, Gen­nao will have some lab space. For now, the com­pa­ny op­er­ates out of a lab on Yale’s cam­pus.

Jim Wil­son

Gen­nao thinks its tech li­censed from Yale can ob­vi­ate the need for vi­ral vec­tor trans­fer com­mon to gene ther­a­pies, which can be dif­fi­cult to make and come with some well-es­tab­lished safe­ty red flags. Gen­nao was in­spired, in part, by the suc­cess of Pas­sage Bio and con­ver­sa­tion with that firm’s co-founder Jim Wil­son.

Pe­te Glaz­er

Wil­son told Glaz­er and Squin­to that even­tu­al­ly the field would have to shift away from the use of virus­es in ther­a­pies. The com­pa­ny has had some suc­cess in pre­clin­i­cal tri­als in mice so far, and if suc­cess­ful, would help rev­o­lu­tion­ize the gene ther­a­py land­scape. That is what drew Squin­to to the role af­ter six years away from run­ning a biotech.

The 25-year vet­er­an who co-found­ed Alex­ion served the com­pa­ny for 23 years. Pri­or to that, he was one of Re­gen­eron’s first em­ploy­ees, and he held a joint aca­d­e­m­ic po­si­tion at both the Tu­lane Uni­ver­si­ty and LSU Med­ical Schools. He has a his­to­ry with biotech star­tups, and though he was ready to step away from the dai­ly grind when he left Alex­ion in 2015, he was rein­vig­o­rat­ed when he stepped in­to an in­ter­im CEO role at Pas­sage Bio. His plan is to get the ball rolling at Gen­nao un­til the com­pa­ny is ready for some­one else to take the reins.

“I wasn’t look­ing to jump back in­to an op­er­at­ing role, but the sto­ry here was so com­pelling, I had to jump back in here,” Squin­to said.

This is the sec­ond gene ther­a­py com­pa­ny from Glaz­er’s lab. In 2019, Tru­code Gene Re­pair launched with am­bi­tious plans of tak­ing on CRISPR with a new, sim­i­lar form of gene edit­ing. Af­ter re­brand­ing to Ve­ra Ther­a­peu­tics, the com­pa­ny switched gears en­tire­ly, though they de­clined to elab­o­rate on the rea­sons be­hind the change, ex­cept to say the tech­nol­o­gy hadn’t failed.

Though the com­pa­ny on­ly has a hand­ful of em­ploy­ees, the funds from Se­ries A will help boost the staff size to to around 20 or 30, he said. Fund­ing will al­so help pro­vide sup­port to se­cure a bat­tery of pre­clin­i­cal da­ta.

The fi­nanc­ing was co-led by Or­biMed, where Squin­to is an ex­ec­u­tive part­ner, and Chau Khuong, an­oth­er part­ner at Or­biMed, will join the board on the round.

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

Remarkable advances in cell and gene therapy over the last decade offer unprecedented therapeutic promise and bring new hope for many patients facing diseases once thought incurable. However, for cell and gene therapies to reach their full potential, researchers, manufacturers, life science companies, and academics will need to work together to solve the significant challenges facing the industry.

Pfiz­er, Sarep­ta and two oth­ers sug­gest Duchenne drug safe­ty is­sues tied to "class ef­fect"

Since the first experimental Duchenne gene therapy programs came about, the space has proven rife with safety issues and patient deaths in clinical trials. Pfizer and three biotechs now think they’ve found a reason why.

The four companies suggested there may be a “class effect” causing the adverse events in Duchenne gene therapies, they wrote in a new study. They specifically highlighted how side effects in five patients across three trials, who all showed muscle weakness with cardiac involvement, were “strikingly similar.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

Biotech is one of the smartest, best educated industries on the planet. PhDs abound. We’ve had a long enough track record to see a new generation of savvy, experienced execs coming together to run startups.

And in these times, they are being tested as never before.

Biotech is going through quite a rough patch right now. For 2 years, practically anyone with a decent resume and some half-baked ideas on biotech could start a company and get it funded. The pandemic made it easy in many ways to pull off an IPO, with traditional road shows shut down in exchange for a series of quick Zoom meetings. Generalist investors flocked as the numbers raised soared into the stratosphere.

Martin Shkreli (Dennis Van Tine/MediaPunch/IPX)

In­fa­mous biotech ex­ec Mar­tin Shkre­li gets out of prison, hits the street

Martin Shkreli, the infamous biotech CEO who made headlines for his jeering assault on a legion of critics in and out of Congress, is back on the streets after 4 years inside a federal penitentiary.

Shkreli’s attorney put out a statement Wednesday afternoon saying that the “pharma bro” had been transferred to a halfway house in New York with a few more months to go under federal custody, slated to end September 14. Attorney Benjamin Brafman acknowledged the release and vowed that he and Shkreli are keeping quiet.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

De­spite fed­er­al ef­forts to di­ver­si­fy clin­i­cal tri­als, progress re­mains 'stag­nan­t' — re­port

While calls to diversify clinical trials have grown louder in recent years — gaining support from federal agencies such as the FDA and NIH — progress has largely stalled, according to a new report from the National Academies of Sciences, Engineering and Medicine.

Swaths of patients in racial and ethnic minority groups, as well as LGBTQIA+, pregnant and older adult populations continue to be left out of clinical trials. While some advances have been made in the last 30 years — women now account for roughly half of clinical trial participants — growth in other areas remains stagnant, according to the report, which was mandated by Congress and sponsored by the NIH.

Paul Chaplin, Bavarian Nordic president and CEO

Bavar­i­an Nordic se­cures BAR­DA con­tract for small­pox vac­cine

It seems that smallpox vaccination production is weighing on the mind of the US government. And manufacturer Bavarian Nordic is the latest company to benefit.

Just a few days after Emergent, a company that has made government contracts its lifeblood, acquired the exclusive rights to Tembexa from Chimerix, with a $225 million cash payment and an expected BARDA contract, the agency has offered a contract for smallpox vaccine production.

Frank Pallone (D-NJ), House Energy and Commerce Committee chair (Kevin Dietsch/Pool via AP Images)

House com­mit­tee unan­i­mous­ly ad­vances FDA user fee leg­is­la­tion with ac­cel­er­at­ed ap­proval tweaks

The House Energy and Commerce Committee on Wednesday offered a rare show of bipartisan support for a bill that would provide the FDA with user fees for the next five years.

The committee voted 55-0 to advance the quinquennial user fee bill to the full House floor, which if approved, will allow the FDA to use biopharma funds to hire new reviewers, and hit new marks as outlined in the user fee deals that the FDA and biopharma companies forged over the past several years.

Lina Khan, FTC chair (Saul Loeb/Pool via AP)

New FTC com­mis­sion­er could turn the tide for an in­ves­ti­ga­tion in­to PBMs

The Senate last week voted along party lines, 51-50, with Vice President Kamala Harris casting the tie-breaker, to make President Biden appointee Alvaro Bedoya the deciding vote on a split 2-2 Federal Trade Commission.

The addition of Bedoya to the FTC could not only spell more trouble for biopharma M&A activity, as he may align with his Democrat partners to break the FTC ties, but it may also mean that FTC Chair Lina Khan has what she needs to move forward on a study around the pharma middlemen known as pharmacy benefit managers.

Henrietta Lacks

UP­DAT­ED: Fed­er­al judge weighs mo­tion to dis­miss HeLa law­suit against Ther­mo Fish­er

The story of Henrietta Lacks’ immortal cell line and her family’s fight for justice caught the attention of national media outlets and Hollywood years ago. Now, the case faces an uncertain fate as a Baltimore federal judge considers tossing the case.

After a hearing on Tuesday, Judge Deborah Boardman is weighing Thermo Fisher’s motion to dismiss the claims against it on the grounds that the statute of limitations has passed, and the continuing harm doctrine does not apply. Boardman is grappling with the “extraordinarily unique facts” of the case, according to Maryland Matters, which first reported the news.